Open AccessDual Fulvestrant‐Trametinib Therapy in Recurrent Low‐Grade Serous Ovarian Cancer
Author(s) -
Bussies Parker L.,
Schlumbrecht Matthew
Publication year - 2020
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2020-0101
Subject(s) - medicine , trametinib , fulvestrant , oncology , ovarian cancer , mek inhibitor , regimen , combination therapy , letrozole , serous fluid , cancer , estrogen receptor , breast cancer , aromatase , mapk/erk pathway , kinase , biology , microbiology and biotechnology
Low‐grade serous ovarian carcinoma (LGSOC) is known to exhibit chemoresistance. Effective treatment options for recurrent disease are few and often limited to hormone antagonism. Combination of endocrine therapies with MEK‐inhibitors displays synergism in preclinical ovarian cancer models, however. This brief communication presents the use of combination anti‐estrogenic and MEK‐inhibitor therapies, fulvestrant and trametinib, as treatment in a heavily pretreated patient with estrogen receptor‐positive, recurrent LGSOC. The dual‐therapy regimen was well tolerated and appeared to confer 9 months of progression‐free survival. Further investigation is warranted to explore this effect.